Memsift Innovations bags $1.62 mn order from global pharma major
The Hindu
Memsift Innovations wins $1.62M contract to revolutionise industrial liquid waste treatment. Pilot program unveiled in 2022, resulting in 90% cost savings, 80% reduction in carbon footprint & 490 tons of CO2 emissions cut annually. Commercial implementation to start in 2024.
Singapore-based Memsift Innovations has bagged a $1.62-million commercial contract from a leading Fortune 100 pharmaceutical company to revolutionise industrial liquid waste treatment and zero liquid discharge solutions.
The global pharma giant initiated a technical feasibility study in 2019. The study aimed to assess the feasibility of utilising TS-30 Improved Membrane Distillation system to treat liquid waste resulted in reducing liquid waste volume by more than 90% while recovering high-quality nitrogen fertiliser, the waste-to-value added product company said in a statement.
Building on the positive outcomes of the feasibility study, a full-scale onsite pilot program was unveiled in early 2022 and has been in continuous operation for over a year.
“This bold move will not only enable the pharma major to achieve more than 90% cost savings in waste disposal but also reduce its carbon footprint by up to 80% compared to conventional disposal and incineration methods, resulting in an estimated reduction of 490 tons of CO2 emissions annually,” said Memsift Innovations Pte. Ltd.’s Founder & CEO J. Antony Prince.
The commercial implementation of this project is slated to begin in the first quarter of 2024.